RB

Robert Barrow

Chief Executive Officer and Board Director

Definium Therapeutics

Therapeutic Areas

Definium Therapeutics Pipeline

DrugIndicationPhase
DT120Major Depressive Disorder (MDD)Phase 3
DT402Autism Spectrum Disorder (ASD)Phase 2a